Palatin Technologies (PTN)
Develops melanocortin agonists for rare obesity disorders through a partner-led pipeline.
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired hypothalamic obesity and Bardet-Biedl syndrome, generated $71.3 million of global revenue during the second quarter of 2026, including $51.0 million in the United States and representing a 19% sequential quarter increase in global sales.
Palatin to Begin Trading on Nasdaq Stock Exchange
PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting the melanocortin receptor system, today announced that its common stock has been approved for listing on the Nasdaq Capital Market and that the Company will transfer its stock exchange listing to Nasdaq from the NYSE American.
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Advancing MC4R-based obesity programs for rare obesity disorders with a focus on improved tolerability and long-term use, and key IND submissions targeted in calendar 2026 and 2027 Programs target rare obesity disorders linked to the MC4R pathway, including hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome Once-weekly injectable MC4R selective peptide agonist remains on track for an IND submission in the fourth quarter of calendar 2026 Oral MC4R selective agonist program is advancing, with a next-generation oral candidate targeted for IND submission in the first half of calendar 2027 Focus is on developing best-in-class MC4R candidates designed to enhance potency, improve tolerability, reduce off-target effects, including those associated with hyperpigmentation, and support safe and effective long-term use Conference call and webcast scheduled for May 13, 2026, at 11:00 a.m. ET PRINCETON, N.J.
Palatin Technologies Q2 Earnings Call Highlights
Palatin Technologies (NYSEAMERICAN:PTN) executives highlighted recent financing activity, progress in the company's melanocortin-4 receptor (MC4R)-based obesity pipeline, and updated financial results during the company's second quarter fiscal 2026 earnings call. Financing strengthens balance sheet and restores NYSE American compliance Chief Financial Officer and Chief Operating Officer Steve Wills said the company completed an upsized $18.2
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Advancing differentiated MC4R-based obesity programs into clinical development Melanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndrome Oral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026 Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving upside Received $3.8 million in upfront consideration Eligible for future milestone payments and royalties Strengthened balance sheet through successful public financing Completed an $18.2 million public offering, including the full exercise of the over-allotment option, on November 12, 2025 Restored NYSE American listing compliance and trading, re-establishing market visibility and liquidity Teleconference and webcast to be held on February 17, 2026 at 11:00 AM ET PRINCETON, N.J., Feb. 17, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal second quarter ended December 31, 2025, and provided a corporate update.
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
Palatin Technologies shares rose in after-hours trading as Janus Henderson Group and its subsidiary reported shared ownership of the company's stock.
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript
Palatin Technologies, Inc. (OTC:PTN) Q1 2026 Earnings Call November 13, 2025 11:00 AM EST Company Participants Carl Spana - Co-Founder, President, CEO & Director Steve Wills - CFO, COO, Executive VP, Treasurer & Secretary Conference Call Participants Scott Henry - Alliance Global Partners, Research Division Presentation Operator Greetings. Welcome to Palatin's First Quarter Fiscal Year 2026 Operating Results Conference Call.
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesity PL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026 Next-generation selective peptide MC4R agonists d esigned for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026 Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025 Received €2.0M ($2.3M) upfront Achieved €5.5M ($6.5M) research milestone in September 2025 $18.2 million public offering, including full exercise of the over-allotment option, closed on November 12, 2025 Regained compliance with NYSE American listing standards – common stock resumed trading under the symbol "PTN" on November 12, 2025 Teleconference and Webcast to be held on Thursday, November 13, 2025, at 11:00 AM EST PRINCETON, N.J. , Nov. 13, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system, today announced financial results for its fiscal first quarter ended September 30, 2025 and provided a corporate update.
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J. , Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common stock (or pre-funded warrants in lieu thereof).
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Oral MC4R agonist PL7737 demonstrated robust weight loss, safety, and high oral bioavailability in preclinical models Clinical data supports co-administration of an MC4R agonist with tirzepatide as a safe, potentially synergistic approach to weight management PL7737 IND-enabling toxicology underway, with an IND submission and clinical trial initiation planned for the first half of 2026; clinical data expected in the second half of 2026 PRINCETON, N.J. , Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the presentation of two posters at ObesityWeek® 2025 in Atlanta, Georgia.
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
$15.8 million at closing with up to an additional $15.8 million upon the cash exercise of the milestone related warrants Regains compliance with NYSE American exchange listing standard - trading of Palatin's common shares will resume on November 12, 2025, under the symbol "PTN" PRINCETON, N.J. , Nov. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its underwritten public offering.
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic macular edema PRINCETON, N.J. , Sept. 22, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company advancing medicines that modulate the melanocortin receptor system, today announced the achievement of a research milestone under its collaboration with Boehringer Ingelheim.
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Boehringer and Palatin Technologies team up to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases
Palatin Announces 1-for-50 Reverse Stock Split
PRINCETON, N.J. , Aug. 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), today announced a reverse stock split ("Reverse Stock Split") of its shares at a ratio of 1-for-50.
Palatin Announces Positive Preclinical Efficacy Data for Oral MC4R Agonist PL7737 in Animal Model of Obesity
Oral PL7737 monotherapy produced rapid and significant weight loss after just 4 days of treatment Combination of oral PL7737 and tirzepatide resulted in additive weight loss effects IND-enabling toxicology program ongoing IND submission planned for 4Q2025; Clinical data expected in 1H2026 PRINCETON, N.J. , July 15, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced strong preclinical results for PL7737, an oral selective melanocortin-4 receptor (MC4R) agonist, showing effectiveness in rodent models of obesity.
Palatin Technologies, Inc. (PTN) Q3 2025 Earnings Call Transcript
Palatin Technologies, Inc. (PTN) Q3 2025 - Earnings Conference Call May 14, 2025 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary Conference Call Participants Scott Henry - Alliance Global Partners Operator Greetings. Welcome to Palatin's Third Quarter Fiscal Year 2025 Operating Results Conference Call.
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and function Topical and systemic administration options enable potential for earlier intervention than current therapies Results support the continued development of PL9654 and PL9655 for the treatment of diabetic retinopathy (DR) CRANBURY, N.J. , May 9, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor system, today announced new preclinical data on its melanocortin agonists PL9654 and PL9655 at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
Palatin Technologies Announces Closing of Reduced Public Offering
Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and accredited investors consisting of 7,324,119 shares of common stock together with Series F warrants to purchase up to 7,324,119 shares of common stock (the "Series F Warrants"), Series G warrants to purchase up to 7,324,119 shares of common stock (the "Series G Warrants"), and Series H warrants to purchase up to 7,324,119 shares of common stock (the "Series H Warrants"), at a combined public offering price of $0.15 per share of common stock and accompanying warrants (the "Offering").